Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab Extension Study in Patients Previously Enrolled in a Roche-Sponsored Pertuzumab Study
NCT02320435Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Feb 2015
- Primary completion
- Dec 2026
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of pertuzumab in solid tumor, sponsored by Roche. Primary endpoints: Progression-Free Survival, Overall Survival and 4 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02320435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320435.